American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis

Kenneth G. Saag, Gee Teng Gim, Nivedita M. Patkar, Jeremy Anuntiyo, Catherine Finney, Jeffrey R. Curtis, Harold E. Paulus, Amy Mudano, Maria Pisu, Mary Elkins-Melton, Ryan Outman, Jeroan J. Allison, Maria Suarez Almazor, S. Louis Bridges, W. Winn Chatham, Marc Hochberg, Catherine Maclean, Ted Mikuls, Larry W. Moreland, James O'DellAnthony M. Turkiewicz, Daniel E. Furst

Research output: Contribution to journalReview articlepeer-review

1247 Scopus citations

Abstract

Guidelines and recommendations developed and/or endorsed by the American College of Rheumatology (ACR) are intended to provide guidance for particular patterns of practice and not to dictate the care of a particular patient. The ACR considers adherence to these guidelines and recommendations to be voluntary, with the ultimate determination regarding their application to be made by the physician in light of each patient's individual circumstances. Guidelines and recommendations are intended to promote beneficial or desirable outcomes but cannot guarantee any specific outcome. Guidelines and recommendations developed or endorsed by the ACR are subject to periodic revision as warranted by the evolution of medical knowledge, technology, and practice.

Original languageEnglish (US)
Pages (from-to)762-784
Number of pages23
JournalArthritis Care and Research
Volume59
Issue number6
DOIs
StatePublished - Jun 15 2008

ASJC Scopus subject areas

  • Rheumatology

Fingerprint

Dive into the research topics of 'American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis'. Together they form a unique fingerprint.

Cite this